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Abstract 
 
The usual approach to determine bioequivalence for highly variable drugs is scaled 
average bioequivalence, which is based on expanding the limits as a function of the 
within-subject variability in the reference formulation. This requires separately 
estimating this variability, and thus using replicated or semi-replicated crossover 
designs. On the other hand, regulations also allow using common 2×2 crossover designs 
based on two-stage adaptive approaches with sample size re-estimation at an interim 
analysis. The choice between scaled or two-stage designs is crucial and must be fully 
described in the protocol. Using Monte Carlo simulations, we show that both 
methodologies achieve comparable statistical power, though the scaled method usually 
requires less sample size, but at the expense of each subject being exposed more times 
to the treatments. With an adequate initial sample size (not too low, e.g., 24 subjects), 
two-stage methods are a flexible and efficient option to consider: They have enough 
power (e.g., 80%) at the first stage for non-highly variable drugs and, if otherwise, they 
provide the opportunity to step up to a second stage that includes additional subjects. 
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1. Introduction 
 
Average bioequivalence (ABE) studies are conducted to demonstrate in vivo either that 
two products, say “test” T and “reference” R, are pharmaceutically equivalent (in the 
US) or that their rate and extent of absorption
1-3
 are close enough to serve as alternative 
pharmaceutical products (in the EU). The most common measure of the rate of 
absorption is the bioavailability measure “maximum observed concentration” (Cmax), 
while the “area under the concentration curves” (AUC0-t and AUC0-∞)
4
 are the most 
common bioavailability measures for the extent of absorption. To demonstrate ABE, 
regulatory guidelines recommend a single dose 2×2 crossover design, RT/TR that 
evaluates T and R on healthy volunteers. The most commonly used criterion to test (at a 
significance level of α = 0.05) for ABE is the “interval inclusion rule”, which is based 
on a 90% symmetric confidence interval for the formulation effect, say the mean 
difference between the bioavailabilities of formulations T and R at a log-transformed 
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scale. It is based on the Student’s distribution, assuming data normality. In order to 
declare ABE, the back-transformed confidence interval for the geometric means ratio 
(GMR) should lie fully within the ABE limits of 0.80−1.25 (=1/0.80), corresponding to 
±0.223 on the logarithmic scale.
2,5
 
 
Highly variable drugs (HVD) are characterized by high within-subject variability in the 
rate and/or extent of absorption of its active principle. This hinders researchers from 
declaring ABE when it really holds, unless unacceptably large sample sizes are used. 
Most regulations classify a drug as HVD if the within-subject coefficient of variation of 
the reference formulation R (CVWR) is 30% or greater on the original scale. The 
percentage of HVD is not negligible. Davit et al
6
 collected data from all in vivo 
bioequivalence studies reviewed by the FDA’s Office of Generic Drugs from 2003 to 
2005, and they concluded that 31% of the studies (57/180) corresponded to highly 
variable drugs, many of them around CVWR = 30%. 
 
If HVD is suspected, the European Medicines Agency (EMA) allows linearly scaling 
the Cmax margins as a function of the R variability to a maximum plateau of 0.6984-
1.4319, and it further allows application of the interval inclusion rule over these 
expanded limits.
2
 Similarly, the FDA also allows researchers to re-scale the AUC 
limits.
1,3
 These scaled approaches require the use of high order crossover designs like 
the replicated TRTR/RTRT or semi-replicated TRR/RTR/RRT designs.
2,7,8
 However, 
these scaled methods, as defined by FDA and EMA regulations, do not adequately 
preserve the type I error rate in the neighborhood of CVWR = 30%.
9,10
 Thus, the 
proportion of non-ABE products erroneously declared as ABE is higher than its desired 
nominal value.  
 
Regulators also allow using two-stage adaptive designs (TSD) with unblinded interim 
sample size re-estimation
2,5,11,12
 based on the usual 2×2 crossover RT/TR design. 
Bioequivalence may be declared at the interim look with N1 subjects; otherwise, the 
sample size can be increased on the basis of the estimated within-subject variability at 
the first stage, then ABE is tested again at a second stage with cumulated data N = N1 + 
N2. Two-stage designs preserve the type I error rate
13
 by adjusting significance 
boundaries at each stage in various ways that are not fully specified in the 
regulations.
14,15
 
 
In turn, the planned sample size is crucial because it may lead to underpowered studies, 
as there is a high uncertainty about the assumed GMR and/or variability.  
 
The main objective of this paper is to critically compare the EMA's original scaled 
method based on a replicate TRTR/RTRT design (or, more precisely, an adjusted variant 
intended to preserve the type I error rate, as shown by Labes and Schütz
10
) with two 
TSD methods based on the usual RT/TR crossover design.  
 
Section 2 describes the compared methods and details the simulation methodology. 
Section 3 shows the results; and Section 4 discusses them in order to recommend the 
most appropriate approach. 
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2. Statistical methodology 
 
2.1. 2010 Regulatory EMA reference scaled average bioequivalence approach (RSABE) 
(for Cmax only) 
 
Replicate TRTR/RTRT designs allow separately estimating the CVWR 
9
 and can easily be 
re-arranged for comparison with a 2×2 crossover design (needed for two-stage designs) 
once the first two periods are sliced (see Section 2.3).  
 
We focus on the EMA regulation because the FDA’s approach is based on scaled limits 
which are discontinuous at CVWR = 30%. This discontinuity is associated with a sharp 
peak of type I probability around this CV value, which threatens its validity.  
 
On the original scale, the null hypothesis of bioinequivalence is tested against an 
alternative of bioequivalence, as follows: 
 
:		 ≤ 	0.80	or		 ≥ 	1.25 
:	0.80 <  < 	1.25. 
 
In the Reference Scaled Average Bioequivalence (RSABE) approach, the ABE limits 
are a function, say , of the unknown population within-subject R coefficient of 
variation , so the hypotheses being tested differ from the standard ones enunciated 
above: 
 
:		 ≤ 	1/()	or		 ≥ 	() 
:	1/() <  < 	(). 
 
If  < 30%, () = 1.25; so the ABE limits are the usual 0.8−1.25. If 
 lies between 30% and 50%, the ABE limits grow as	() = 
 !	{#$%&'(( + 1)}, with # = 0.76. Otherwise, from = 50%, 
() = 1.4319; so the ABE limits stay constant at 0.6984 (= 1/1.4319). 
 
A short statement of the EMA testing decision criterion is: 
 
(1) Obtain the GMR estimate,	0 = 12 , where 34 is the estimated formulation effect 
3, the mean difference of test and reference products of the corresponding log 
Cmax scale; 
(2) Point estimate constraint: If 0  is outside the limits 0.8-1.25, do not declare 
bioequivalence and stop; 
(3) Obtain the estimate of the within-subject coefficient of variation of the reference 
product, 5 = 	$6789
: − 1, where <=(  is the estimated value of the reference 
residual standard deviation in the logarithmic scale; 
(4) Obtain the 90% confidence interval for GMR around its estimate 0 , >?0 =
[∅2B,∅2D]	, where ∅2F and ∅2G are the estimated lower and upper limits of the 
confidence interval in the logarithmic scale, at a confidence level of 1 − 2H for α = 
0.05 
(5) If >?0  is fully included in the (5) limits, declare ABE (reject ), 
otherwise do not declare ABE. 
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Note that the limits I5J are random, not fixed constants like 0.8 or 1.25, 
since they depend on the random quantity 5, which is not fixed in advance. 
 
Muñoz et al,
9
 among others, showed that the above decision criterion does not 
adequately control the type I error probability, or false positive rate (say, if 
bioequivalence is erroneously declared when in fact it does not hold) in the 
neighborhood of  = 30%.  
 
2.2. Significance level adjustment on the Regulatory EMA scaled approach 
 
As has been previously stated, the 2010 former EMA RSABE procedure does not 
control completely the type I error probability. To focus on an easy to use method for 
practitioners, and with chances to be included in the regulations, we considered the 
method already implemented in the function “scABEL.ad” in the R package 
PowerTOST.
10
 As a consequence of adjusting the significance level, the EMA’s scaled 
method (labeled AdjEMA in the table results) may lose some power. But this (small in 
general) loss of power is worth because it converts a potentially invalid procedure (with 
respect to the type I erro  probability) in a fully correct one. 
 
As a function of the reference coefficient of variation, the type I error probability has 
only one single maximum at CVWR = 30%. Consequently, though somewhat 
conservatively, we let the argument “CV” of scABEL.ad at its default value of 0.3. The 
alternative strategy of estimating the coefficient of variation from data and assigning 
this (random function of data, unknown in advance) value to the argument CV induces 
some type I error probability inflation. 
 
In accordance with EMAs Questions & Answers guideline,
11
 section 10, the estimation 
of the required parameters was based on the ANOVA procedure labelled as “Method A” 
in this document, and not in the intra-subject contrasts, as are for example allowed in 
the FDA regulation for scaled average bioequivalence. 
 
2.3. Two-stage modified Potvin B and C designs 
 
We consider two adaptive two-stage designs (TSD) with one interim analysis (at the 
first stage) with N1 subjects to either (1) establish equivalence early; or (2) stop for 
futility; or (3) recruit an additional group of N2 subjects to repeat the bioequivalence 
assessment at a second stage with N = N1 + N2 subjects. Each stage is based on a 2×2 
crossover balanced RT/TR design, and so the within-subject variability  should be 
estimated by means of the pooled variability of R and T. Unlike the scaled approach, 
two-stage hypotheses always rely on the standard fixed limits 0.8–1.25.  
 
Among adaptive approaches to bioequivalence,
15
 we focused on those (almost partially) 
mentioned in regulations, considering two “Pocock-like” variants,
16
 as described by 
Potvin et al. and labelled A, B, C and D.
17
 In particular, we studied a Type 1
5
 Potvin B 
method consisting of using the same adjusted α in both stages regardless of whether a 
study stops in the first stage or proceeds to the second stage (Figure 1), and a Type 2 
Potvin C method where an unadjusted α may be used in the first stage, dependent on 
interim power (Figure 2). 
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Both methods calculate N2 as the minimum even number of additional subjects required 
for having a total sample size of N, which achieves a conditional power of at least 80% 
for declaring bioequivalence at the second stage. This is conditional on the estimated 
within-subject coefficient of variation 5 at the first stage for an assumed true GMR 
of 0.95. 
 
Potvin A was discarded, as it did not adjust the significance boundaries; Potvin D was a 
more conservative variant of Potvin C, and therefore not recommended because it 
requires larger average sample sizes than Potvin C.
13
 
 
We propose a modification to the original Potvin B and C algorithms, including two 
constraints consisting of using a minimum sample size in the second stage (like in other 
jurisdictions or organizations),
5
 and a maximum overall number of 150 subjects 
enrolled
18,19
 in ABE studies, as follows: 
 
- A minimum of N ≥ 1.5N1 is required (or N2 ≥ 0.5N1) 
- If N = N1 + N2 > 150, the trial fails and it is stopped at the first stage. 
 
In any case, regardless of the method used, at least 12 evaluable subjects should be 
included in the first stage.
1,11
 
The adjusted significance level of α = 0.0294 used by Potvin et al
13,16,17,18
 at each stage 
did not always control the overall type I error rate at a maximum 0.05 (e.g., when using 
our modified Potvin C algorithm with N1 = 12 and considering a true unknown CVW = 
20%, the false positive rate would be inflated to 0.053). Like in Xu et al,
20
 we did look 
for a significance level by strictly controlling the type I error rate below 0.05, which 
was useful for our specific modified Potvin B and C methodologies. Because the 
sponsor is unaware of the true CVW value, we looked for a significance level which was 
applicable to a broad set of N1 and , {N1/CVW} (scenarios shown in Section 2.5.). 
We used the method implemented in the function “power.2stage” (via non-central t-
distribution) in the R package Power2Stage. The treatment effect was evaluated at the 
frontier 1.25, and assuming an expected GMR = 0.95 and a target power of 80%.  
A short statement for assessing the adjusted significance level, αadj: 
 
(1) Define a grid with a set of {N1/CVW}  
(2) Start with an arbitrary, e.g. αadj = 0.0290 
(3) Obtain the empirical probability of type I error, Pr{TIE}, over the grid (m = 30,000 
simulation trials per scenario). Filter for the scenarios where Pr{TIE} is at least 
95% of the max(Pr{TIE}) observed in the grid, let’s say {N1/CVW}TIE≥P95% 
(4) For {N1/CVW}TIE≥P95%, find the N1/CVW with max(Pr{TIE}) (m = 1,000,000) 
(5) Set up a range of αj close to the one used before, HK ∈ MHNOK ± QKRKS…U (e.g. by δ 
increments of 0.0001 units). By using the N1/CVW associated to max(Pr{TIE}), 
estimate the Pr{TIE} of all αj (m = 1,000,000) 
(6) Adjust linear α = glin(Pr{TIE}) and quadratic α = gquad(Pr{TIE}) models, with and 
without the intercept. Choose the model with the lowest Akaike information 
criterion value (AIC) 
(7) Use this model to predict a new αadj, where αadj = g(0.05)  
(8) Evaluate the entire grid of {N1/CVW} with this new αadj (m = 1,000,000) 
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(9) If Pr{TIE} < 0.05 for all {N1/CVW}, STOP and select this new αadj; Otherwise, start 
again over with step (4) 
 
As the 2010 EMA guideline uses a Type 1 TSD method,
2
 we used the modified Potvin 
B as the main TSD approach and the modified Potvin C as a sensitive case. 
 
2.5. Simulation methods 
 
The results described in the next sections are based on simulations using 64 bits R and 
Microsoft R Open. The main outputs are: type I error rate, power and the number of 
trials stopping at the first stage for the TSD approach. For most scenarios, m = 100,000 
datasets were generated, but m = 1,000,000 for those devoted to estimating the most 
crucial type I error probabilities, i.e., for simulated GMRs just on the bioequivalence 
limit. 
 
In the simulations, we considered all combinations of 3 factors: sample size, true GMR 
and true within-subject variability under the homoscedasticity assumption that		 =
	 = V (from now on, we use CVW and CVWR interchangeably, provided the 
assumed simulated homoscedasticity). The sample sizes were N1 = 12, 18, 24, 30, 36, 
48 and 60 subjects for RSABE methods and at the first stage for TSD methods, always 
considering a balanced design, i.e.: 6, 9, 12, 15, 18, 24 and 30 subjects per sequence. 
The simulated population GMR values were 0.95, 1.00, 1.12, 1.25 and 1.31; with the 
first three corresponding to scenarios under true bioequivalence (alternative hypothesis), 
and the last two corresponding to the true non-bioequivalence (null hypothesis). In fact, 
this statement is exactly true for the TSD approach, where the bioequivalence limits are 
the constants 0.80−1.25; see the next paragraph for clarification in the RSABE case. 
Finally, the simulated within-subjects coefficients of variation were 10%, 20%, 25%, 
30%, 40%, 50% and 60%. A coefficient of variation of 30% or higher indicates an 
HVD. Section 3 reports only the results for a subset of the simulated values on sample 
size, true GMR, and true coefficient of variation. In addition, these TSD simulations 
were done using the “exact” method. 
Provided that TSD and RSABE are based on different definitions of bioequivalence, 
comparing them is quite difficult. In order to have a reference case for comparison, we 
took the simulated true GMR values “on the frontier” of each approach (constant 1.25 in 
TSD or a function  in RSABE for varying simulated  values), which 
should provide similar proportions of bioequivalence declaration (near 0.05) if both 
approaches are adequately controlling the user’s risk.  For GMRs that are progressively 
inside or outside the corresponding bioequivalence regions, these probabilities should 
also be comparable. To define these concordant simulation scenarios, we reasoned at the 
logarithmic scale. The constant simulated GMR values in the TSD approach are 0.95, 
1.00, 1.12, 1.25 and 1.31, and they correspond to formulation effects on the logarithmic 
scale of −0.0513, 0, 0.1133, 0.2231 and 0.2700, respectively. With respect to the 
(frontier) 0.2231 value, these formulation effects correspond to proportions λ = −0.230,  
0,  0.508,  1 and  1.210, respectively. Then, λ = 1 refers to values on the frontier, |λ| < 1 
to scenarios of true bioequivalence, and |λ| > 1 to scenarios of bioinequivalence. 
Therefore, the same λ value defines concordance in TSD and RSABE scenarios: the 
population GMRs in the original scale were taken as exp{λ 0.2231} in the TSD 
approaches, and for all simulated  values; while in the RSABE approach, they 
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were taken as exp{λ 0.2231} for  < 30%, as  ! XY#$%&'(( + 1)Z for 
CVWR values between 30% and 50%, and as exp{λ 0.3590} for a  ≥ 50%. 
 
For simplicity, the simulated GMRs in the next sections will always be labeled as 0.95, 
1.00, 1.12, 1.25 and 1.31; but it should be remembered that these values in the RSABE 
case correspond only to the simulated coefficients of variation below 30%. 
 
Following the EMA Questions & Answers guideline,
11
 adjusted ANOVA models for 
analysis of the combined second stage data included the following terms: stage, 
sequence, interaction sequence*stage, subject nested in sequence*stage, period nested in 
stage, and formulation.  
 
3. Simulation results 
 
The adjusted significance level predicted for the modified Potvin B was assessed at αadj 
= 0.0301 at each stage; For the modified Potvin C, the adjusted significance level 
predicted was assessed at αadj = 0.0280 (Figures 1 and 2). 
 
Both adaptive TSD modified Potvin B and C methods performed similarly in respect to 
the power achieved and the required median sample size Me[N] (Table 1). Because 
almost all simulated studies required stepping up to a second stage and resulted in large 
final sample sizes, it was not advisable to start with a too small sample size, like N1 = 
12, in scenarios with  high variability ( ≥ 30%).  
 
On the other hand, when N1 ≥ 24, the global power (including both stages) was at least 
80% when variabilities were raised up to 40%. Additionally, those sample sizes 
increased the likelihood of stopping for bioequivalence at the first stage. For the high 
value of  = 60%, results were poor, with power always below 80%.  
 
For the RSABE EMA method, a crucial variability value is at the threshold  =
30%, where there is a maximum type I error peak. Table 2 shows that for a true  of 
1.25 the highest false positive rate is 0.085, confirming the already known risk control 
problems of the EMA scaled approach. On the other hand, the RSABE adjusted EMA 
method (AdjEMA) accurately respected the nominal 0.05 level. Both TSD approaches 
also respected the type I error at 0.05. In addition, for a sample size of N1 = 24, all 
methods with a type I error close to the nominal 0.05 level provide satisfactory and 
similar powers on bioequivalent drugs (GMR = 0.95, 1.00, and 1.12). The apparently 
larger sample sizes required by TSD methods should be relativized: with half periods, 
they did not double mean size and reached a bioequivalence statement at the first stage 
in a notable proportion of times (approximately 41%, 47% and 24%).  
 
Figure 3 shows a more comprehensive picture of the extended N1 and  values for a 
bioequivalent scenario fixed at GMR = 0.95. When N1 = 12, TSD methods showed 
higher power than the RSABE adjusted EMA method for  > 20%, requiring 
relatively larger global sample sizes of Me[N] = 44 and around 70 for  =
30%	and		40%, respectively. For N1 = 24 the RSABE adjusted EMA method showed a 
similar trend as both TSD methods; and for N1 = 36, both methods showed power above 
80%, for a true  below 60%. For a true  ≥ 60%, the power for both TSD 
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methods seriously suffered from the futility criterion of not allowing studies with more 
than 150 subjects, though for the RSABE adjusted EMA the power was still above 80%.  
 
Figure 4 explores the power for different true levels of bioequivalence: GMR = 0.95, 
1.00, and 1.12. It is remarkable that for a true value of GMR = 1.12, no methods reached 
80% power for any HVD with  ≥ 30%. 
 
4. Discussion 
 
Bioequivalence studies are the pivotal clinical studies submitted to regulatory agencies 
to support the marketing applications of new generic drug products. High levels of 
within-subject variability make it difficult to assess bioequivalence through standard 
procedures using reasonable sample sizes, thus delaying treatment. After many years of 
discussion, some agencies issued regulations describing those methods. In general, their 
approach is based on bioequivalence limits being scaled as a function of the reference 
formulation variability. This is the reference scaled average BE (RSABE) approach of 
the EMA regulation issued in 2010.
2
 Although also mentioned in the regulations, 
adaptive two-stage designs (TSD) are not used nearly as much as the widespread scaling 
methods, despite having some appealing characteristics. Deciding on the study’s 
experimental design is crucial and must be done in advance (e.g., including it in the 
study protocol), generally without full knowledge of the within-subject variability. We 
compared two variants of well-known adaptive methods and an RSABE adjusted (type I 
error) EMA approach. Both methods showed similar statistical power, but the RSABE 
adjusted scaled method required less sample size, although at the expense of exposing 
subjects twice as long as TSD methods. For initial sample sizes of at least 24 subjects, 
TSDs are a good option to consider, as they have a power of around 80% at the first 
stage for non-highly variable drugs while at the same time they offer the opportunity for 
stepping up to the second stage (including additional subjects) for truly bioequivalent 
products. 
 
Statistical power is used to evaluate the performance of adaptive methodologies in ABE 
clinical trials. A power of at least 80% is desirable when considering N1 subjects at the 
first stage, and assuming an expected but unknown within-subject coefficient of 
variation, CVw. In turn, this is always conditioned to not exceed the overall type I error 
rate of 0.05 for true bioinequivalent drugs. In our modified Potvin B and C methods, we 
found adjusted significance levels covering a wide range of N1 and CVw combinations 
(i.e. αadj = 0.0301 and αadj = 0.0280 at each stage for Potvin B and C, respectively). This 
is useful to regulators since they can widely rely on the protection of patients against 
false positive results. However, we understand that for a specific actual (local) N1 and 
CVw combination, the power might be slightly downgraded, although it is always above 
80% in case of true bioequivalence. 
 
Patterson et al
21
 explored the sample size that provides 90% power (for true 
bioequivalent drugs) in case of HVD. They showed that by using 2x2 crossover designs 
with conventional ABE limits of 0.8-1.25 and CVw of 60% or above, the required 
sample size exceeds 150 subjects (though replicate designs require smaller sample size). 
Using adaptive designs, we avoid conducting studies with such a large sample size by 
imposing a futility criterion so that we can stop the trial at an interim look with only N1 
subjects. According to Karalis and Macheras,
19
 we added a constraint to the original 
TSD methods, specifically by not recruiting more than 150 subjects overall. For 
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example, in the case of a true bioequivalent drug with 0.95 ≤ GMR ≤ 1.05, and for 
highly variable drugs with an estimated within-subject coefficient of variation above 
58% at the interim analysis, the final sample size needed for achieving a power of 80% 
at the second stage already exceeds 150 subjects. At first glance this constraint 
represents some global loss of power, but this possibility of cancelling a study for 
futility may ultimately be considered a positive trait, since the sponsor is unaware of the 
true treatment effect value during the planning phase, and the overall sample size could 
unnecessarily soar above this threshold for a scenario of true bioinequivalence. 
However, from an ethical perspective even starting a study with such a low expected 
power might be questionable.
22
 
 
Kieser and Rauch
15
 and Karalis and Macheras
19
 pointed out a potential limitation of the 
original TSD methods stated by Potvin et al
17
 and Montague et al,
13
 as although 
unblinded data are available after the first stage, the knowledge about the estimated 
GMR in the interim analysis is not used for sample size recalculation. We assumed a 
fixed true treatment effect of GMR = 0.95 after the first stage since Cui et al
23
 showed 
that a determination of the second stage sample size based on an interim estimate of the 
GMR can substantially inflate the probability of type I error in most practical situations. 
 
In addition, the expected total sample size E[N] is usually used to compare the 
performance characteristics of different TSD methods. However, by their very nature in 
TSD, the distribution of total sample sizes N is bimodal, mainly due to the imposition of 
N ≥ 1.5N1. For example, using our modified Potvin B, with αadj = 0.0301 at each stage, 
GMR = 0.95, CVw = 0.3, N1 = 24, and target power 80%, we obtain a E[N] of 40 
subjects, but with 24 and 36 subjects having more likelihood of occurrence (Figure 5). 
As the average is skewed towards two sample values, we believe that the median of N is 
more useful to compare different TSD methods. 
 
In general, regulators allow using adaptive methods, though they usually favor sample 
size re-estimation procedures that maintain the blinding of the treatment allocations 
throughout the trial, as shown by Golkowski et al.
24
 However, even though both TSD 
Potvin B and C methods studied in this article assume unblinded data at the interim 
analysis, the agencies do specifically also recommend using these two TSD methods,
2
 
as they have demonstrated that they control the type I error rate in a strong way. 
 
So, given that either the RSABE or TSD methods are suitable approaches for ABE 
studies, we have compared them through the behavior of the type I error rate and its 
power to facilitate the discussion about which to choose. In terms of power, both 
approaches perform similarly despite both adaptive methods requiring a higher mean 
sample size to reach the same power, especially for clearly variable drugs. Nevertheless, 
they demonstrate suitable power at the first stage in some cases. However, as RSABE 
relies on replicate designs, double exposure of subjects is needed. The crucial point to 
consider is the assessment made by sponsors regarding the relative importance of the 
number of required subjects (an argument favoring the scaled approach) and the 
exposure of these subjects (which tips the balance in favor of the TSD approach). 
 
The applicability of the TSD approaches is essentially the same as the classical 
approach, in that they have the same RT/TR design and fixed standard limits.
25
 The 
RSABE approaches (with type I error adjustment) are appropriate for drugs with low to 
moderate variability, because dose-to-dose variability within a patient is comparable to 
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the width of the criteria. However, with HVD, dose-to-dose variability within a patient 
is greater than the width of the standard criteria, and it is usually characterized by flat 
dose response curves and wide safety margins. Therefore, broadening the acceptance 
limits in the RSABE approach is at the very least controversial, since clinically sound 
criteria should be used to clearly prove if a greater difference in Cmax (and also in AUC 
for the FDA) is irrelevant. 
 
In conclusion, the RSABE approach is well powered and usually requires enrolling 
fewer patients than adaptive TSD methods, even though scaling the ABE limits 
ultimately depends on additional clinical judgment. For HVD in general, samples of 36 
subjects provided well-powered studies using RSABE methods. As there is a 
considerable chance of declaring ABE at the first stage in adaptive approaches, sponsors 
should consider them because they imply less subject exposure and less treatment 
duration.  
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Table 1. Two-stage design (TSD) modified Potvin B and C: Bioequivalence, sample size, and percentage of studies stepping up to 
second stage for true GMR = 0.95, and under different fixed N1 and a true CVw 
 
 Modified Potvin B Modified Potvin C 
Fixed a 
priori 
ABE 
Step 
to 
St2 
N ABE 
Step 
to 
St2 
N 
N1 
True 
CVw 
% St1 
% 
St1+St2 
% Min 5% Me 95% Max 
% 
St1 
% 
St1+St2 
% Min 5% Me 95% Max 
12 20 41.92 85.00 55.69 12 12 18 40 104 41.56 84.76 54.44 12 12 18 40 106 
12 30 7.03 78.61 92.71 12 12 44 84 150 6.40 78.34 93.05 12 12 44 84 150 
12 40 1.03 71.65 95.68 12 22 70 128 150 0.90 70.96 95.28 12 20 72 130 150 
12 60 0.05 29.43 51.00 12 12 44 142 150 0.05 27.76 49.06 12 12 12 142 150 
24 20 83.76 90.16 8.20 24 24 24 36 62 87.89 91.19 4.22 24 24 24 24 64 
24 30 41.86 83.86 57.47 24 24 36 70 138 40.47 83.38 57.69 24 24 38 72 140 
24 40 10.12 79.79 89.45 24 24 76 118 150 8.93 79.44 90.49 24 24 78 120 150 
24 60 0.19 31.19 46.47 24 24 24 146 150 0.15 28.83 43.59 24 24 24 146 150 
36 20 95.68 95.75 0.07 36 36 36 36 54 97.51 97.51 0.01 36 36 36 36 54 
36 30 68.13 87.23 28.33 36 36 36 60 120 69.94 85.77 22.95 36 36 36 62 124 
36 40 34.32 82.42 65.54 36 36 68 110 150 32.40 82.14 67.16 36 36 72 112 150 
36 60 1.53 31.28 42.66 36 36 36 146 150 1.20 28.35 39.37 36 36 36 146 150 
ABE, average bioequivalence; TSD, two-stage design; GMR, geometric mean ratio; N1, initial and fixed sample size (Stage 1); CVw, within-subject coefficient of 
variation; %St1, proportion of simulations declaring bioequivalence at Stage 1; %St1+St2, cumulative proportion of simulations declaring ABE at Stage 2, Step up 
to St2, proportion of simulations requiring stepping up from Stage1 to Stage 2; Min, min of N; 5%, percentile 5 of N; Me, median of N; 95%, percentile 95 of N; 
Max, max of N; 
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Table 2. Probability of bioequivalence acceptance according to the regulatory 
reference scaled ABE (RSABE) EMA and an adjusted EMA method compared to 
two-stage designs (TSD) modified Potvin B and C (true CVw = 30%) 
 
  Probability ABE 
acceptance 
Type I error 
  True GMR 
 Method 0.95 1.00 1.12 1.25 1.31 
R
S
A
B
E
 
m
e
th
o
d
 
Regulatory EMA (N1 = 24) 0.896 0.963 0.631 0.085 0.021 
AdjEMA (N1 = 24) 0.864 0.948 0.559 0.050 0.009 
T
S
D
 
m
e
th
o
d
 
Modified Potvin B (N1 = 24 at 
Stage 1) 
0.419 
 
0.484 
 
0.242 
 
0.029 
 
0.008 
 
Modified Potvin B (Stage 1 + 
Stage 2 with 36≤N≤150)  
0.839 0.926 0.527 0.050 0.012 
Modified Potvin C (N1 = 24 at 
Stage 1) 
0.405 
 
0.468 
 
0.236 
 
0.030 
 
0.009 
 
Modified Potvin C (Stage 1 + 
Stage 2 with 36≤N≤150) 
0.834 0.922 0.519 0.048 0.012 
ABE, average bioequivalence; RSABE, reference scaled average bioequivalence; TSD, two-stage design; 
GMR, geometric mean ratio; CVw, within-subject coefficient of variation; N1, initial and fixed sample 
size fixed at 24 subjects (Stage 1 with modified Potvin B and C); Regulatory EMA, regulatory European 
Medicines Agency approach; AdjEMA, adjusted EMA type I error 
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Legends 
 
Figure 1. Type 1 TSD Modified Potvin B algorithm 
 
Adapted from the figure depicted in detail by Montague et al,
13 
with the restriction of Karalis and 
Macheras
18
 of not including more than 150 subjects and N ≥ 1.5N1;  
ABE, average bioequivalence; N1, Initial fixed sample size; N2, the additional number of subjects 
recruited at Stage 2; GMR, assumed geometric mean ratio; 5, estimated within-subject coefficient of 
variation 
 
Figure 2. Type 2 TSD Modified Potvin C algorithm 
 
Adapted from the figure depicted in detail by Montague et al,
13 
with the restriction of Karalis and 
Macheras
18
 of not including more than 150 subjects
 
and N ≥ 1.5N1;  
ABE, average bioequivalence; N1, Initial fixed sample size; N2, the additional number of subjects 
recruited at Stage 2; GMR, assumed geometric mean ratio; 5, estimated within-subject coefficient of 
variation 
 
Figure 3. Bioequivalence acceptance of the adjusted reference scaled ABE 
(RSABE) EMA method and two-stage designs (TSD) modified Potvin B and C at 
stages 1 and 2, for a true GMR of 0.95, and a progressive increase of the within-
subject variability 
 
ABE, average bioequivalence; RSABE, reference scaled average bioequivalence; TSD, two-stage 
design; GMR, geometric mean ratio; HVD, highly variable drugs; N1, initial and fixed sample size used 
for the modified EMA method and both TSD methods at Stage1; CVw, within-subject coefficient of 
variation; Me[N], TSD media total sample size at Stage 2 (beside the squares in the figure); AdjEMA, 
type I error adjusted EMA method 
 
Figure 4. Bioequivalence acceptance of the adjusted reference scaled ABE (RSABE) 
EMA method and two-stage designs (TSD) modified Potvin B for different levels of true 
bioequivalence and a progressive increase in the within-subject variability 
 
ABE, average bioequivalence, RSABE, reference scaled average bioequivalence; TSD, two-stage design; HVD, 
highly variable drugs; N1, initial and fixed sample size (EMA method); GMR, geometric mean ratio; CVw, 
within-subject coefficient of variation; Me[N], TSD median total sample size (beside the squares in the figure); 
AdjEMA, type I error adjusted EMA 
 
Figure 5. Type 1 TSD modified Potvin B distribution of N (Stag1 + Stage 2) 
GMR=0.95; CVw=30%; N1=24; αadj =0.03018396; P=0.8; m=1,000,000 simulations 
 
GMR, true geometric mean ratio; CVw, true within-subject coefficient of variation; N1, Initial fixed 
sample size; N2, the additional number of subjects enrolled at stage 2; N=N1+N2, total sample size 
(stage 1 + stage 2); αadj, significance level used in each stage; P. target power; m, number of 
simulations 
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312x220mm (300 x 300 DPI)  
 
 
Page 19 of 23 Statistics in Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 2. Type 2 TSD Modified Potvin C algorithm  
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Figure 3. Bioequivalence acceptance of the adjusted reference scaled ABE (RSABE) EMA method and two-
stage designs (TSD) modified Potvin B and C at stages 1 and 2, for a true GMR of 0.95, and a progressive 
increase of the within-subject variability  
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Figure 4. Bioequivalence acceptance of the adjusted reference scaled ABE (RSABE) EMA method and two-
stage designs (TSD) modified Potvin B for different levels of true bioequivalence and a progressive increase 
in the within-subject variability  
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Figure 5. Type 1 TSD modified Potvin B distribution of N (Stag1 + Stage 2)  
GMR=0.95; CVw=30%; N1=24; αadj =0.03018396; P=0.8; m=1,000,000 simulations  
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